Jana Tresnak Hercogova

Prof. Dr. Jana Tresnak Hercogova

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2019 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
JHJana Tresnak Hercogova
Jana Tresnak Hercogova
KPK.A. Papp
K.A. Papp
VCV. Chyrok
V. Chyrok
MUM. Ullmann
M. Ullmann
PVP. Vlachos
P. Vlachos
CEC.J. Edwards
C.J. Edwards
Background MSB11022 is a proposed adalimumab biosimilar. Objectives To compare the efficacy, safety and immunogenicity of MSB11022 with reference adalimumab. Methods AURIEL‐PsO was a double‐blind randomised controlled equivalence trial, in which patients with moderate‐to‐severe chronic plaque‐type psoriasis were randomised 1:1 to MSB11022 or reference adalimumab. The primary endpoint was Psoriasis Area and Severity Index (PASI) 75 at Week 16, with a prespecified equivalence interval of ±18%. Patients with a ≥50% improvement in PASI at Week 16 were eligible to enter a double‐blind extension period: patients receiving MSB11022 continued treatment, and patients receiving reference adalimumab were re‐randomised 1:1 to either continue reference adalimumab or switch to MSB11022. Other efficacy endpoints, safety, immunogenicity and pharmacokinetic parameters were evaluated at scheduled visits up to Weeks 52 (efficacy and immunogenicity), 54 and 66 (safety). Results In total, 443 patients were randomised. The difference in PASI 75 response rates at Week 16 between the treatment arms was ‐1·9%, and the 95% confidence interval (‐7·82%, 4·07%) was within the prespecified equivalence interval. No notable difference in the incidence of treatment‐emergent adverse events was observed between treatment arms up to the end of the trial, and no new safety signals were observed. Following treatment switch at Week 16, no clinically meaningful differences in safety or immunogenicity were seen between treatment arms through to the end of the observation period. Conclusions Therapeutic equivalence between MSB11022 and reference adalimumab was demonstrated. AURIEL‐PsO provides evidence to support the similarity of both products with regard to efficacy, safety and immunogenicity.

16 November 2021 in Cells
Verified
Journal Article
Open access
PDF file
DSDagmar Schierova
Dagmar Schierova
RRRadka Roubalová
Radka Roubalová
MKMartin Kolar
Martin Kolar
ZSZuzana Stehlikova
Zuzana Stehlikova
FRFilip Rob
Filip Rob
ZZZuzana Jiraskova Zakostelska
Zuzana Jiraskova Zakostelska
Inflammatory bowel diseases (IBD) are chronic disorders of the gastrointestinal tract that have been linked to microbiome dysbiosis and immune system dysregulation. We investigated the longitudinal effect of anti-TNF therapy on gut microbiota composition and specific immune response to commensals in IBD patients. The study included 52 patients tracked over 38 weeks of therapy and 37 healthy controls (HC). To characterize the diversity and composition of the gut microbiota, we used amplicon sequencing of the V3V4 region of 16S rRNA for the bacterial community and of the ITS1 region for the fungal community. We measured total antibody levels as well as specific antibodies against assorted gut commensals by ELISA. We found diversity differences between HC, Crohn’s disease, and ulcerative colitis patients. The bacterial community of patients with IBD was more similar to HC at the study endpoint, suggesting a beneficial shift in the microbiome in response to treatment. We identified factors such as disease severity, localization, and surgical intervention that significantly contribute to the observed changes in the gut bacteriome. Furthermore, we revealed increased IgM levels against specific gut commensals after anti-TNF treatment. In summary, this study, with its longitudinal design, brings insights into the course of anti-TNF therapy in patients with IBD and correlates the bacterial diversity with disease severity in patients with ulcerative colitis (UC).

22 January 2025 in Immunotherapy
Verified
Journal Article
Open access
EGEmma Guttman-Yassky
Emma Guttman-Yassky
ESEric L. Simpson
Eric L. Simpson
RBRobert Bissonnette
Robert Bissonnette
LELawrence F. Eichenfield
Lawrence F. Eichenfield
KKKenji Kabashima
Kenji Kabashima
GKGregory Kricorian
Gregory Kricorian
Atopic dermatitis (AD) is a chronic inflammatory disease affecting ~ 10% of adults and ~ 20% of children globally. Many patients with moderate-to-severe AD receiving systemic therapies, including biologics and Janus kinase (JAK) inhibitors, fail to reach or maintain treatment goals due to lack of durable response or safety/tolerability issues. Rocatinlimab is a T-cell rebalancing therapy that inhibits and reduces pathogenic T cells by targeting the OX40 receptor. ROCKET, a large, global phase 3 program of eight clinical trials (NCT05398445; NCT05651711; NCT05724199; NCT05899816; NCT05704738; NCT05633355; NCT05882877; NCT06224192), will evaluate the efficacy, durability of response, and long-term safety of rocatinlimab as monotherapy and combination therapy in adult and adolescent patients with moderate-to-severe AD with or without prior exposure to biologics or systemic JAK inhibitors.

1 November 2012 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
TLTorello M. Lotti
Torello M. Lotti
JHJana Tresnak Hercogova
Jana Tresnak Hercogova
RSRobert A. Schwartz
Robert A. Schwartz
DTDionigi Tsampau
Dionigi Tsampau
IKIgor Korobko
Igor Korobko
GBGionata Buggiani
Gionata Buggiani

31 May 2017 in International Journal of STD & AIDS
Verified
Journal Article
Open access
HSHelmut Schöfer
Helmut Schöfer
STSilvio Tatti
Silvio Tatti
CLCharles Lynde
Charles Lynde
MSMihael Skerlev
Mihael Skerlev
JHJana Hercogová
Jana Hercogová
Piergiacomo Calzavara-PintonPiergiacomo Calzavara-Pinton
Piergiacomo Calzavara-Pinton
This review about the proactive sequential therapy (PST) of external genital and perianal warts (EGW) is based on the most current available clinical literature and on the broad clinical experience of a group of international experts, physicians who are well versed in the treatment of human papillomavirus-associated diseases. It provides a practical guide for the treatment of EGW, including epidemiology, etiology, clinical appearance, and diagnostic procedures for these viral infections. Furthermore, the treatment goals and current treatment options, elucidating provider- and patient-applied therapies, and the parameters driving treatment decisions are summarized. Specifically, the mode of action of the topical treatments sinecatechins and imiquimod, as well as the PST for EGW to achieve rapid and sustained clearance is discussed. The group of experts has developed a treatment algorithm giving healthcare providers a practical tool for the treatment of EGW which is very valuable in the presence of many different treatment options.

1 January 2012 in Dermatologic Therapy
Verified
Journal Article
Closed access
PDF file
NVNaděžda Vojáčková
Naděžda Vojáčková
JFJorga Fialová
Jorga Fialová
DVDaniela Vaňousová
Daniela Vaňousová
JHJana Hercogová
Jana Hercogová
The study describes the case of a patient with a clinical and histopathological diagnosis of pemphigus vulgaris accompanied by severe side‐effects of combined immunosuppressive therapy, who achieved a remission of the disease with adalimumab. Pemphigus vulgaris is a chronic blistering disease of the skin and mucous membranes. Before corticosteroids were introduced, mortality was high. Corticosteroids are currently used as first‐line therapy. To reduce the dose of corticosteroids, therapeutic combinations with corticosteroid‐sparing immunosuppressive agents are used. The therapy brings a number of complications due to its side effects. To achieve a remission of the disease by treating our patient with combined immunosuppressives, we administered adalimumab and achieved a very good clinical response.